Acute liver disease associated with sodium valproate

Area of Science:

• Hepatology
• Pediatric Medicine
• Clinical Pharmacology

Background:

• Sodium valproate is a widely prescribed anticonvulsant and mood-stabilizing drug.
• Liver injury is a known, albeit rare, adverse effect associated with valproate therapy.
• Monitoring for hepatotoxicity is crucial in patients receiving long-term valproate treatment.

Observation:

• A cohort of five patients, including four children, developed acute liver disease.
• The onset of liver disease occurred 3-6 months after commencing sodium valproate therapy.
• Associated symptoms included thrombocytopenia and hair loss, common side effects of sodium valproate.

Findings:

• Acute liver disease is a serious potential adverse event linked to sodium valproate.
• The hepatotoxicity manifested several months into treatment, suggesting a cumulative or delayed effect.
• The high mortality rate in this small cohort underscores the severity of the observed liver injury.

Implications:

• Clinicians should exercise caution when prescribing sodium valproate, especially in pediatric populations.
• Enhanced vigilance and early diagnostic measures for liver function are warranted in patients on sodium valproate.
• Further research into the mechanisms of valproate-induced hepatotoxicity and risk stratification is essential.